MFG
CRSP icon

Merit Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Merit Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$579K Buy
10,613
+511
+5% +$26.9K ﹤0.01% 1419
2026
Q1 		$481K Buy
10,102
+169
+2% +$8.91K ﹤0.01% 1395
2025
Q4 		$521K Sell
9,933
-524
-5% -$31.4K ﹤0.01% 1290
2025
Q3 		$678K Buy
+10,457
New +$600K 0.01% 1025

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Merit Financial Group's CRSP Position: Q2 2026 in Review

Merit Financial Group increased its CRISPR Therapeutics (CRSP) stake by 5.1% in Q2 2026, buying an estimated $26.9K and bringing the position to 10,613 shares worth $579K. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Merit Financial Group first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $678K in Q3 2025. 62 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Merit Financial Group held 10,613 shares of CRISPR Therapeutics worth $579K as of Q2 2026.
  • Merit Financial Group bought 511 CRISPR Therapeutics shares in Q2 2026, an estimated $26.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1419 holding.
  • Merit Financial Group first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Merit Financial Group's CRISPR Therapeutics position peaked at $678K in Q3 2025.
  • 62 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.